Belatacept Injection 250 mg/vial Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 250 mg/vial

Reference Brands: Nulojix(US)

Category: Transplant

Belatacept is a fusion protein that blocks CD80/CD86 on immune cells, preventing T-cell activation. It effectively reduces kidney transplant rejection, supports long-term graft survival, and decreases the need for intensive immunosuppressants. Benefits include targeted immunosuppression, fewer side effects, and improved quality of life for transplant recipients.

Product Description: Belatacept, marketed as Nulojix, is approved in the US by the FDA and in the EU via EMA for rejection prevention in adult kidney transplant recipients. Regulatory approval requires comprehensive dossiers, including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews detailed clinical trial and quality information, while the EMA ensures compliance with regional safety and manufacturing regulations. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Ensuring proper regional adherence supports timely approval, safe use, and global availability, helping transplant patients achieve optimal long-term outcomes and graft survival worldwide.